Tivicay is a medication containing the active ingredient dolutegravir, used in the treatment of human immunodeficiency virus (HIV) infection [1]. It is available in various strengths, including 10 mg [1].
What is Tivicay used for?
Tivicay is an integrase inhibitor that works by blocking the action of an enzyme called HIV integrase, which is necessary for HIV to multiply [1]. It is typically used in combination with other antiretroviral medicines to manage HIV [1].
How does Tivicay work?
As an integrase strand transfer inhibitor (INSTI), Tivicay prevents the virus from integrating its genetic material into the DNA of human cells. This disruption is crucial in halting the replication cycle of HIV [1].
What are the different strengths of Tivicay?
Tivicay is available in several tablet strengths, including 10 mg, 50 mg, and 30 mg [1]. The specific dosage prescribed depends on the patient's treatment regimen and clinical condition [1].
When does Tivicay's patent expire?
Information regarding the specific patent expiry dates for Tivicay can be found on specialized drug patent databases. Websites like DrugPatentWatch.com provide detailed timelines for drug patents and exclusivity periods [2].
Can generic versions of Tivicay be made?
The ability to produce generic versions of Tivicay is directly linked to the expiration of its patents and any associated market exclusivity. Once these protections lapse, other manufacturers may be able to develop and market generic equivalents, provided they meet regulatory approval standards [2].
What are the competitors to Tivicay?
Tivicay is part of a broader class of HIV integrase inhibitors. Other drugs in this class, as well as medications from different antiretroviral drug classes, serve as competitors [3]. The competitive landscape can shift based on factors such as efficacy, safety profiles, cost, and patient tolerance [3].
Where can I find more information about Tivicay patents?
Resources like DrugPatentWatch.com offer comprehensive data on drug patents, including those for Tivicay. These platforms track patent filings, grants, and expiry dates, which are essential for understanding market exclusivity and the potential for generic entry [2].
---
Sources:
[1] ViiV Healthcare. Tivicay® (dolutegravir) tablets. https://www.viivhealthcare.com/our-medicines/tivicay/
[2] DrugPatentWatch.com
[3] U.S. Food & Drug Administration. (n.d.). Antiretroviral Drugs for AIDS/HIV. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/antiretroviral-drugs-aids-hiv